Update of the pivotal phase 1/2 TRIDENT-1 trial

During a recent update of the TRIDENT-1 trial, Prof Dr Byoung Chul Cho, a medical oncologist at Yonsei Cancer Center in Seoul, South Korea, presented positive results for repotrectinib, a next-generation ROS1 tyrosine kinase inhibitor (TKI) in patients with locally advanced and metastatic ROS1+ NSCLC. The trial showed that at a median follow-up of 20 months, repotrectinib provided durable clinical activity in patients with ROS1+ NSCLC. In TKI-naïve patients, the median duration of response and progression-free survival were 34.1 months and 35.7 months, respectively. Clinically meaningful activity was also seen in TKI-pretreated patients. The safety of repotrectinib was found to be manageable.  In a discussion with Dr. Mariana Brandao, he also provided insights into the management of dizziness that can occur in patients treated with repotrectinib. These findings suggest that repotrectinib could be a new standard of care option for patients with ROS1+ locally advanced or metastatic NSCLC, both in TKI-naïve and TKI-pretreated patients.

With the educational support of: